HOME >> BIOLOGY >> NEWS
Blood test shows promise as monitor for antiangiogenic cancer therapy

Scientists have uncovered critical information that may lead to an urgently needed method for effective monitoring of antiangiogenic cancer therapies. The research, published in the January issue of Cancer Cell, is likely to facilitate development of new antiangiogenic drugs or treatment strategies and allow for accurate determination of the optimal drug doses to use for such therapies.

Antiangiogenic cancer therapy targets the formation of new blood vessels used to support tumor growth. Although many of these agents are currently being tested in clinical trials, no reliable way to monitor the effects of many, if not most, of these therapeutic agents on the inhibition of the complicated process of angiogenesis exists. Dr. Robert S. Kerbel from Women's College Health Sciences Centre in Toronto and colleagues, including Dr. Francesco Bertolini of the European Institute of Oncology in Milan and Dr. Robert D'Amato of Harvard University, examined whether circulating levels of a class of specific blood cells that contribute to the formation of tumor vessels provide any useful information about the effectiveness of angiogenesis inhibitors.

The researchers found that levels of circulating endothelial cells (CECs) and circulating endothelial progenitor cells (CEPs) are quite varied depending on the genetic background of an animal. However, within a particular strain of mice, levels of these cells are influenced by known regulators of blood vessel formation and correlate remarkably with the ability to induce tumor blood vessel growth and the response to antiangiogenic therapy. Importantly, treatment with a drug that interfered with the major signaling receptor for vascular endothelial growth factor (VEGF), a key regulator of blood vessel development, caused a dose-dependent reduction in CEPs. The reduction in CEPs closely reflected the previously established antitumor activity of this VEGF inhibitor, and the optimal decline in CECs and CEPs was reached
'"/>

Contact: Heidi Hardman
hhardman@cell.com
1-617-397-2879
Cell Press
17-Jan-2005


Page: 1 2

Related biology news :

1. Blood test may help signal tumors remission, return in throat cancer patients
2. Blood sugars manufacture limited by building blocks supply
3. Bloods clotting cells harbor ticking time bombs, finding may help extend blood supply
4. Blood tests may be possible for mental health conditions
5. Cord Blood Registry achieves industry-leading stem cell recovery with new automation technology
6. Blood test predicts cardiac events and death in heart patients
7. Blood clot fibers more elastic than spiders web
8. Blood-compatible nanoscale materials possible using heparin
9. Blood pressure medication may revolutionize treatment of Marfan syndrome
10. Blood levels of suspected carcinogen vary by race, ethnicity
11. Blood conservation strategies take center stage at Emory University Hospital forum

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/6/2019)... ... , ... Keck Graduate Institute (KGI) President Sheldon Schuster has announced Martin Zdanowicz ... “Dean Zdanowicz is highly regarded as an innovative leader who prioritizes student success and ... choice to build on the success of the KGI School of Pharmacy and Health ...
(Date:8/4/2019)... ... August 02, 2019 , ... Bioclinica, a leading provider ... the development of medical therapies, announced today that Michael O’Neal, M.D., Chief Medical ... the “100 Most Inspiring People in the Life-Sciences Industry.” Dr. O’Neal was ...
(Date:8/1/2019)... ... July 31, 2019 , ... ... the launch of the next generation of its FLIPR® Penta High-Throughput Cellular Screening ... industry-leading FLIPR® platform for monitoring of G-protein-coupled receptors (GPCRs) and ion channels, offering ...
Breaking Biology News(10 mins):
(Date:7/23/2019)... N.J. (PRWEB) , ... July 22, 2019 , ... ... and biotech companies with best-in-class services in the fields of 3D tissue ... machine learning , Visikol initially started back in 2013 as a products ...
(Date:7/17/2019)... ... July 16, 2019 , ... ... manufacturing of Zolgensma® (onasemnogene abeparvovec-xioi), an AveXis gene therapy treatment for spinal ... have dedicated manufacturing space at the new, state-of-the-art commercial manufacturing center near ...
(Date:7/9/2019)... ... 2019 , ... Balluff has been named a 2019 “Best ... Innovative Product of the Year which highlights cutting-edge advancements and achievements that are ... & Conference 2019, held this week in San Jose, California. , Utilizing ...
(Date:6/18/2019)... ... June 18, 2019 , ... Personalized Stem Cells, Inc ... application to the FDA for use of a person’s own adipose-derived stem cells to ... osteoarthritis in the knee. This IND is the first of several planned clinical ...
Breaking Biology Technology:
Cached News: